Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Multiple Sclerosis

• Publication date

  2012-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1352458510394702PMID 21228025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

  2011cited by this paper
• A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

  2010cited by this paper
• Magnetic resonance evidence of cortical onset of multiple sclerosis

  2009cited by this paper
• Cortical lesions in primary progressive multiple sclerosis

  2009cited by this paper
• Accumulation of cortical lesions in MS: relation with cognitive impairment

  2009cited by this paper
• Brain atrophy as an outcome measure for multiple sclerosis clinical trials

  2009cited by this paper
• A 3‐year magnetic resonance imaging study of cortical lesions in relapse‐onset multiple sclerosis

  2009cited by this paper
• Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study

  2009cited by this paper
• Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study

  2009cited by this paper
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

  2009cited by this paper
• Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.

  2009cited by this paper
• Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

  2008cited by this paper
• Extensive cortical inflammation is associated with epilepsy in multiple sclerosis

  2008cited by this paper
• Grey matter pathology in multiple sclerosis.

  2008cited by this paper
• Gray matter involvement in multiple sclerosis

  2007cited by this paper
• Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

  2007cited by this paper
• Extensive Hippocampal Demyelination in Multiple Sclerosis

  2007cited by this paper
• Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.

  2007cited by this paper
• Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis.

  2007cited by this paper
• Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits?

  2006cited by this paper
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• Localization of grey matter atrophy in early RRMS

  2006cited by this paper
• The measurement and clinical relevance of brain atrophy in multiple sclerosis.

  2006influential reference
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Cortical demyelination and diffuse white matter injury in multiple sclerosis.

  2005cited by this paper
• Gray and white matter volume changes in early RRMS

  2005cited by this paper
• Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype.

  2005cited by this paper
• Grey Matter Pathology in Multiple Sclerosis

  2005cited by this paper
• Relating neocortical pathology to disability progression in multiple sclerosis using MRI

  2004cited by this paper
• Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients

  2003cited by this paper
• The clinico‐radiological paradox in multiple sclerosis revisited

  2002influential reference
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS

  2001cited by this paper
• Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

  2001cited by this paper
• Diagnostic criteria for multiple sclerosis.

  2001cited by this paper
• A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

  2001cited by this paper
• Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

  2001cited by this paper
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  2000cited by this paper
• Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.

  1999cited by this paper
• Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis

  1999cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

  1991influential reference
• Comparing individual means in the analysis of variance.

  1949cited by this paper

• Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study

  2025cites this paper
• Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis

  2024cites this paper
• Neuropsychological Manifestations of Multiple Sclerosis.

  2024cites this paper
• Decoding Gray Matter Involvement in Multiple Sclerosis via Imaging.

  2024cites this paper
• Imaging cortical lesions in multiple sclerosis

  2023cites this paper
• Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis

  2023cites this paper
• MRI features and disability in multiple sclerosis: A systematic review and meta-analysis.

  2023cites this paper
• Comparison of dimethyl fumarate and interferon outcomes in an MS cohort

  2022cites this paper
• Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: A systematic review and network meta-analysis.

  2022cites this paper
• Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis.

  2022cites this paper
• Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage

  2022cites this paper
• Efficacy classification of modern therapies in multiple sclerosis.

  2021cites this paper
• IFI35 as a biomolecular marker of neuroinflammation and treatment response in multiple sclerosis.

  2020cites this paper
• User experience for manual injection of 2 mL viscous solutions is enhanced by a new prefillable syringe with a staked 8 mm ultra-thin wall needle

  2020cites this paper
• New approaches for testing non-inferiority for three-arm trials with Poisson distributed outcomes.

  2020cites this paper
• Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.

  2020cites this paper
• Astrocyte Glutamate Uptake and Water Homeostasis Are Dysregulated in the Hippocampus of Multiple Sclerosis Patients With Seizures

  2020cites this paper
• Anti-inflammatory and cognitive effects of interferon-β1a (IFNβ1a) in a rat model of Alzheimer’s disease

  2019cites this paper
• Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.

  2019cites this paper
• ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

  2018cites this paper
• Transformation of Radiologically Isolated Syndrome into Tumefactive Multiple Sclerosis

  2018cites this paper
• Brain Morphometry in Multiple Sclerosis

  2018cites this paper
• Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis

  2018cites this paper
• ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

  2018cites this paper
• The effect of fingolimod on focal and diffuse grey matter damage in active MS patients

  2018cites this paper
• Estriol‐mediated neuroprotection in multiple sclerosis localized by voxel‐based morphometry

  2018cites this paper
• Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives

  2018cites this paper
• Comparative effectiveness of interferons in relapsing–remitting multiple sclerosis: a meta-analysis of real-world studies

  2017cites this paper
• A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis

  2017cites this paper
• Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.

  2017influential citation
• A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.

  2017cites this paper
• Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach

  2017cites this paper
• A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis

  2017cites this paper
• Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

  2017cites this paper
• The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in Italy

  2017cites this paper
• Cortical Involvement in Multiple Sclerosis

  2017cites this paper
• Surrogate Markers in Multiple Sclerosis: The Role of Magnetic Resonance Imaging

  2016cites this paper
• Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States

  2016cites this paper
• Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis

  2016cites this paper
• An Exploratory Investigation of Social Stigma and Concealment in Patients with Multiple Sclerosis.

  2016cites this paper
• The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada

  2016cites this paper
• Psychological interventions for enhancing adherence to disease‐modifying therapies (DMTs) in multiple sclerosis

  2016cites this paper
• Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

  2016cites this paper
• No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study)

  2016cites this paper
• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

  2016cites this paper
• Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.

  2015cites this paper
• Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosis

  2015cites this paper
• The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.

  2015cites this paper
• The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection

  2015cites this paper
• Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression in Relapsing-Remitting Multiple Sclerosis: Results from a 48-Month Extension Study

  2015cites this paper
• A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis

  2015cites this paper
• Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy

  2015cites this paper
• Cognitive Reserve as a Useful Concept for Early Intervention Research in Multiple Sclerosis

  2015cites this paper
• Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis.

  2015cites this paper
• Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

  2015cites this paper
• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

  2014cites this paper
• Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink?

  2014cites this paper
• Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial.

  2014cites this paper
• Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

  2014cites this paper
• Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis

  2014cites this paper
• Therapeutic strategies for relapsing–remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy

  2014cites this paper
• Grey matter atrophy in patients suffering from multiple sclerosis.

  2014cites this paper
• Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment.

  2014cites this paper
• A 10-year follow-up of people with multiple sclerosis-aspects of disability and health, use of and satisfaction with care, and feasibility of cognitive behavioural therapy

  2014cites this paper
• Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations

  2013cites this paper
• Neuronal pathology in targeted cortical experimental autoimmune encephalomyelitis and multiple sclerosis

  2013cites this paper
• Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis

  2013cites this paper
• Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study

  2013cites this paper
• A review of current and emerging therapeutic strategies in multiple sclerosis.

  2013cites this paper
• Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

  2013cites this paper
• Third ventricular enlargement in early stages of multiple sclerosis is a predictor of motor and neuropsychological deficits: a cross-sectional study

  2013cites this paper
• Advanced magnetic resonance imaging in pediatric multiple sclerosis.

  2013cites this paper
• MRI in the Prediction and Diagnosis of Pediatric-onset Multiple Sclerosis: Insights from Children with Incident CNS Demyelination

  2013cites this paper
• Measurement and clinical effect of grey matter pathology in multiple sclerosis.

  2012cites this paper
• Clinical correlates of grey matter pathology in multiple sclerosis

  2012cites this paper
• The puzzle of multiple sclerosis: gray matter finds its place

  2011cites this paper
• Modeling the Distribution of New MRI Cortical Lesions in Multiple Sclerosis Longitudinal Studies

  2011influential citation
• Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis

  2010cites this paper